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Summary
Background The role and dose of anticoagulants in thromboprophylaxis for patients with cancer receiving chemotherapy 
through central venous catheters (CVCs) is controversial. We therefore assessed whether warfarin reduces catheter-related 
thrombosis compared with no warfarin and whether the dose of warfarin determines the thromboprophylactic eﬀ ect.
Methods In 68 clinical centres in the UK, we randomly assigned 1590 patients aged at least 16 years with cancer who 
were receiving chemotherapy through CVCs to no warfarin, ﬁ xed-dose warfarin 1 mg per day, or dose-adjusted warfarin 
per day to maintain an international normalised ratio between 1·5 and 2·0. Clinicians who were certain of the beneﬁ t 
of warfarin randomly assigned patients to ﬁ xed-dose or dose-adjusted warfarin groups. The primary outcome was the 
rate of radiologically proven, symptomatic catheter-related thrombosis. Analysis was by intention to treat. This trial is 
registered as an International Standard Randomised Controlled Trial, number ISRCTN 50312145.
Findings Compared with no warfarin (n=404), warfarin (n=408; 324 [79%] on ﬁ xed-dose and 84 [21%] on dose-adjusted) 
did not reduce the rate of catheter-related thromboses (24 [6%] vs 24 [6%]; relative risk 0·99, 95% CI 0·57–1·72, 
p=0·98). However, compared with ﬁ xed-dose warfarin (n=471), dose-adjusted warfarin (n=473) was superior in the 
prevention of catheter-related thromboses (13 [3%] vs 34 [7%]; 0·38, 0·20–0·71, p=0·002). Major bleeding events were 
rare; an excess was noted with warfarin compared with no warfarin (7 vs 1, p=0·07) and with dose-adjusted warfarin 
compared with ﬁ xed-dose warfarin (16 vs 7, p=0·09). A combined endpoint of thromboses and major bleeding showed 
no diﬀ erence between comparisons. We did not note a survival beneﬁ t in either comparison. 
Interpretation The ﬁ ndings show that prophylactic warfarin compared with no warfarin is not associated with a 
reduction in symptomatic catheter-related or other thromboses in patients with cancer and therefore we should 
consider newer treatments.
Funding Medical Research Council and Cancer Research UK.
Introduction
Venous thromboembolism is a well known complication 
of cancer and is related to the production of a range of 
procoagulant factors by tumours, certain chemotherapies 
and hormone therapies, and the use of central venous 
catheters (CVCs). Evidence of venous thromboembolism 
is found at post-mortem examination in about 50% of 
patients with cancer,1 but remains an underdiagnosed 
and undertreated condition. The use of CVCs to deliver 
infusional chemotherapy has increased enormously in 
the past decade as has recognition of catheter-related 
thrombosis as a source of considerable morbidity.2 
Hitherto, trials of thromboprophylaxis for adult patients 
with cancer undergoing CVC-administered chemotherapy 
have not produced a clear consensus on the role of 
anticoagulation. Diﬀ erent deﬁ nitions of catheter-related 
thrombosis and inconsistent assessment of venous 
thromboembolism have made comparisons diﬃ  cult.
The ﬁ ndings of two small studies3,4 in the 1990s 
suggested that prophylactic anticoagulation reduces the 
rates of thrombosis with no apparent bleeding. However, 
results of trials done since the start of this century have 
challenged this thinking and have not shown an 
advantage of anticoagulant intervention in the reduction 
of thrombosis rates for patients receiving CVC-
administered chemotherapy.5–8
A survey of clinical opinion of thromboprophylaxis in 
patients receiving infusional chemotherapy through a CVC 
was undertaken in 1999; we used the ﬁ ndings from this 
survey to inform our study. The results of the survey, 
completed by more than 200 cancer clinicians in the UK, 
indicated that 60% administered warfarin routinely for 
thromboprophylaxis (95% of these clinicians prescribed 
1 mg per day) and 20% of clinicians were certain of the 
indication for warfarin intervention and hence would not 
be willing to randomly assign patients to a no-warfarin 
comparison arm. 
We investigated whether warfarin reduces catheter-
related thrombosis compared with no warfarin, and 




68 clinical centres in the UK with nursing teams 
dedicated to catheter care participated in the trial. Patients 
were eligible if they had a histologically conﬁ rmed 
diagnosis of cancer, needed CVC insertion for 
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administration of chemotherapy, were aged at least 16 years, 
and had adequate hepatic, renal, and haematological 
functions. Patients were excluded if they had a 
contraindication to warfarin, were already taking 
warfarin, or were pregnant or lactating.
The clinical centres received ethical approval from the 
West Midlands multicentre research ethics committee. All 
patients provided written informed consent.
Trial design
The study design, based on the principle of uncertainty, 
was structured to encompass contemporary clinical 
opinion noted from the pretrial survey. Clinicians who 
were uncertain of the beneﬁ ts of warfarin for 
thromboprophylaxis, randomly assigned patients no 
warfarin, ﬁ xed-dose warfarin at 1 mg per day, or 
dose-adjusted warfarin to maintain the international 
normalised ratio (INR) between 1·5 and 2·0. Clinicians 
who were certain of the beneﬁ ts of warfarin randomly 
assigned patients to ﬁ xed-dose or dose-adjusted 
warfarin. Patients were aware of the group to which they 
were assigned. All preferences were those of the 
clinicians. Initially, the uncertain-indication preference 
had three arms; however, investigators subsequently 
requested the inclusion of a two-arm option of no 
warfarin versus ﬁ xed-dose warfarin (ﬁ gure 1). The 
steering committee amended the trial design accordingly 
after 141 patients were assigned to the uncertain 
three-arm comparison and 245 to the certain preference 
comparison. We randomly assigned patients using 
computerised block algorithm. We stratiﬁ ed patients on 
the basis of three thrombosis risk factors: sclerosant 
potential of the chemotherapy regimen (low or high); 
site of insertion of their catheters (peripheral or central); 
and duration of their drug infusion (<24 h or >24 h, for 
duration of one chemotherapy cycle intravenous 
infusion).
Treatment plan
We allowed the use of all types of CVCs in the study. We 
checked the correct position of the catheter tip (at the 
junction of the superior vena cava and right atrium) by 
chest radiography after CVC insertion. We allowed 
randomisation and start of warfarin, if allocated, from 
3 days before CVC insertion (to enable suﬃ  cient exposure 
to warfarin for the immediate postinsertion period). 
Patients took oral warfarin (adminstered from local 
hospital pharmacies) every day until thrombosis occurred 
or the catheter had to be removed for any reason and 
patients were able to temporarily discontinue treatment 
in the event of thrombocytopenia (platelets ≤50×10⁹ per L). 
We provided agreed protocols for INR monitoring in all 
treatment arms and treatment of venous thrombo-
embolism was in accordance with local practice. 
Outcome measures
The primary outcome measure was the rate of 
radiologically conﬁ rmed symptomatic catheter-related 
thrombotic events—ie, those occurring in the venous 
system draining the catheter or pulmonary emboli in 
patients who had catheter complications. Secondary 
outcome measures were non-catheter-related thrombotic 
events (in the arterial system, in the venous system not 
draining the catheter, and pulmonary emboli in patients 
with no catheter complications), catheter patency, 
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Figure 1: Trial proﬁ le
Comparisons were no warfarin (n=161+243=404) versus warfarin (n=242+82+84=408) within the warfarin-evaluation arm, and ﬁ xed-dose warfarin 
(n=82+389=471) with dose-adjusted warfarin (n=84+389=473) in the dose-evaluation arm.
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INR), overall survival, catheter-related infections, and 
health-service-related costs (not reported here). All 
thromboses were radiologically conﬁ rmed by venography, 
ultrasonography, or ventilation-perfusion or spiral CT 
scans, and classiﬁ ed as catheter-related or non-catheter-
related by two investigators, unaware of treatment 
allocation, using a central protocol. We recorded 
thromboses that were suspected but not radiologically 
conﬁ rmed as CVC complications. We deﬁ ned major 
bleeding episodes as intracranial, retroperitoneal, 
requiring transfusion or hospital admission, or directly 
leading to death.9 Investigators classiﬁ ed increased INR 
as mild (>2 and <5), moderate (≥5 and <8), or severe 
(≥8). Investigators obtained the dates of death from the 
case-record forms or from the Oﬃ  ce of National Statistics 
in April, 2007. 
Statistical analysis
We made sample-size calculations on the basis of 
assumptions that the thrombotic-event rate for patients 
on no warfarin was about 25% and if warfarin was to 
reduce this rate by 10% then the improvement would be 
medically worthwhile. With 800 patients entered into the 
uncertain indication (400 no warfarin and 400 warfarin), 
the power to detect a 10% diﬀ erence would be greater 
than 90%. With 1000 patients randomly assigned to 
either of the warfarin doses (500 to ﬁ xed-dose and 500 to 
dose-adjusted), the power to detect a diﬀ erence of 7% in 
thrombotic-event rates between the two dosing schedules 
would be 80%. The trial had about 90% power to detect a 
10% diﬀ erence in long-term survival when we compared 
warfarin and no-warfarin groups.
We compared rates of thrombotic events using 
Mantel-Haenszel χ² tests, stratiﬁ ed by randomisation, 
and expressed diﬀ erences between treatments as relative 
risk (RR) with 95% CIs. We did the analysis on an 
intention-to-treat basis, with a small number of 
unknown-outcome patients combined with those who 
did not have an event. Sensitivity analysis conﬁ rmed the 
validity of the assumption. We analysed catheter-related 
thrombotic events as time to event data with time to 
thrombosis censored at date of CVC removal in those 
patients without an event. Additionally, we compared the 
time to thrombosis in patients with an event using 
Wilcoxon tests. We calculated the duration of catheter 
patency as time from catheter insertion to thrombotic 
event, CVC complication, or CVC removal for those 
patients without an event. We analysed the overall 
survival, measured from date of randomisation to date 
of death or date last seen alive, with Kaplan-Meier10 
estimation and log-rank tests.11 We compared major 
bleeding episodes using Fisher’s exact test. All p values 
were two-sided.
This trial is registered as ISRCTN 50312145.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study at the ﬁ nal analysis and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
We recruited 1590 patients between October, 1999, and 
December, 2004. Comparisons could only be made for 
randomised groups, hence those receiving warfarin under 
the certain preference could not be included in the 
assessment of warfarin versus no warfarin.  We compared 
rates of thromboses in patients allocated to no warfarin 
(n=404) with those allocated to any warfarin (n=408). We 
compared outcomes in patients assigned a ﬁ xed dose of 
warfarin (n=471) with an adjusted dose (n=473).
Table 1 shows the baseline patient and CVC 
characteristics, which are well balanced across the study 
arms. Figure 1 shows the trial proﬁ le. The study design 
meant that 166 (10%) patients contributed to both 
comparisons—ie, any warfarin with no warfarin, and 
ﬁ xed-dose with adjusted-dose warfarin. In the uncertain 









Sex (male) 247 (61%) 252 (62%) 253 (54%) 265 (56%)
Age (years) 61 (53–68) 60 (53–68) 59 (51–66) 60 (53–67)
WHO functional/physical health performance status
0 221 (55%) 225 (55%) 263 (56%) 272 (58%)
1 168 (42%) 151 (37%) 178 (38%) 161 (34%)
2/3 10 (2%) 21 (5%) 23 (5%) 29 (6%)
Not known 5 (1%) 11 (3%) 7 (1%) 11 (2%)
Stage of disease
Early/no residual 130 (32%) 134 (33%) 171 (36%) 138 (29%)
Advanced 273 (68%) 269 (66%) 294 (62%) 330 (70%)
Not known 1 (<1%) 5 (1%) 6 (1%) 5 (1%)
Disease site
Colorectal 201 (50%) 217 (53%) 226 (48%) 243 (51%)
Upper gastrointestinal tract 109 (27%) 92 (23%) 95 (20%) 98 (21%)
Breast 32 (8%) 32 (8%) 82 (17%) 67 (14%)
Other 50 (12%) 54 (13%) 52 (11%) 49 (10%)
Not known 12 (3%) 13 (3%) 16 (3%) 16 (3%)
Catheter placement
Central 146 (36%) 150 (37%) 226 (48%) 228 (48%)
Peripheral 258 (64%) 258 (63%) 245 (52%) 245 (52%)
Sclerosant potential
Non-sclerosant 172 (43%) 169 (41%) 235 (50%) 236 (50%)
Sclerosant 232 (57%) 239 (59%) 236 (50%) 237 (50%)
Treatment length
<24 h 64 (16%) 68 (17%) 87 (18%) 86 (18%)
≥24 h 340 (84%) 340 (83%) 384 (82%) 387 (82%)
Data are number (%) or median (IQR). 
Table 1: Baseline patient characteristics
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preference group, 324 (79%) patients received ﬁ xed-dose 
warfarin 1 mg per day and 84 (21%) received dose-adjusted 
warfarin (ﬁ gure 1). The total number of patients from 
these two arms (n=408), constituted the warfarin group.
Clinicians from 68 centres assigned patients to the 
trial—133 (76%) always assigned patients to the same 
preference (61 [35%] to certain preference  and 72 [41%] 
to uncertain preference for the beneﬁ t of warfarin). 
42 (24%) clinicians assigned patients under both 
preferences. Within diﬀ erent centres, diﬀ erent clinicians 
had diﬀ erent preferences. 
Four of 1590 patients were ineligible—three because of 
clinical parameters and one declined chemotherapy 
immediately after randomisation. Four patients did not 
have CVCs inserted after randomisation, 12 did not 
receive any allocated warfarin (eight on ﬁ xed-dose 
warfarin and four on dose-adjusted warfarin), mostly 
because of personal choice. Of 1186 patients allocated to 
warfarin, 1139 were known to have started treatment (20 
did not start and there were no data for 27). For 26 (2%) 
of 1139 patients on warfarin, the patients or their 
clinicians, or both, did not adhere to the warfarin dose. 
For ﬁ ve of these patients allocated to ﬁ xed-dose warfarin, 
the clinician prescribed the variable dose; and 20 of 
21 patients on dose-adjusted warfarin took 1 mg per day 
by mistake or by choice. All patients were included in the 
analysis (webﬁ gure).
The protocol stated that warfarin should be taken 
until the catheter was removed or thrombosis occurred. 
Of 1139 patients who started treatment, only 155 (14%) 
started 3 days before the catheter was inserted. Of those 
who started treatment, 106(9%) stopped early (ie, 
>7 days before the catheter was removed), largely 
because they completed chemotherapy and the CVC 
was still in situ, but also because of personal choice or 
the occurrence of thrombocytopenia. Time of cessation 
of treatment was balanced across treatment arms. Data 
for warfarin compliance were incomplete for 99 (6%) of 
1590 patients (webﬁ gure shows the detailed compliance 
data).
85 (5%) of 1590 patients had a radiologically conﬁ rmed 
catheter-related thrombotic event. Warfarin did not reduce 
the rate of this outcome compared with no warfarin 
(table 2). By contrast, signiﬁ cantly fewer catheter-related 
thromboses occurred in patients assigned to dose-adjusted 
warfarin compared with ﬁ xed-dose warfarin. Analysis of 
this primary outcome as time-to-event data showed 
similar results (ﬁ gure 2). A further 36 (2%) patients had a 
non-catheter-related thrombotic event. Neither warfarin 
(compared with no warfarin) nor dose-adjusted warfarin 
(compared with ﬁ xed-dose warfarin) had any signiﬁ cant 
eﬀ ect on all thrombotic events (table 2). The inclusion of 
clinically suspected thromboses that were not 
radiologically conﬁ rmed (one in warfarin group vs four in 
no-warfarin group; one in dose-adjusted warfarin group 
vs ﬁ ve in ﬁ xed-dose group) in a sensitivity analysis of all 
thromboses did not change the above conclusions (p=0·17 
for warfarin vs no warfarin, and p=0·06 for dose-adjusted 
warfarin vs ﬁ xed-dose warfarin). Table 3 shows no 
signiﬁ cant diﬀ erences in the comparisons of ﬁ xed-dose 
and dose-adjusted warfarin groups separately with no 
warfarin. 
The sites of catheter-related thromboses were upper 
limb (n=32), axillary vein (n=17), subclavian vein (n=16), 
internal jugular (n=10), superior vena cava (n=4), lung 
(pulmonary emboli; n=2), catheter (n=2), and site not 











Relative risk (95% CI, 
p value)
Thrombotic events
Catheter-related thrombotic events 24 (6%) 24 (6%) 0·99 (0·57–1·72, 0·98) 34 (7%) 13 (3%) 0·38 (0·20–0·71, 0·002)
No catheter-related event 370 (92%) 372 (91%) ·· 433 (92%) 448 (95%) ··
Not known 10 (2%) 12 (3%) 4 (<1%) 12 (3%)
All thrombotic events (catheter-related and non-catheter-related) 38 (9%) 30 (7%) 0·78 (0·50–1·24, 0·30) 37 (8%) 26 (6%) 0·70 (0·43–1·14, 0·15)
No thrombotic event 356 (88%) 368 (90%) ·· 430 (91%) 438 (93%) ··
Bleeding and raised INR
Major bleeding and no reported raised INR 1 (<1%) 3 (<1%) ·· 5 (1%) 7 (1%) ··
Major bleeding and raised INR 0 4 (<1%) ·· 2 (<1%) 9 (2%) ··
Total major bleeding 1 (<1%) 7 (2%) 6·93 (0·86–56·08, 0·07) 7 (1%) 16 (3%) 2·28 (0·95–5·48, 0·09)
Moderate and severe raised INR and no major bleeding 0 3 (<1%) ·· 1 (<1%) 12 (3%) ··
Minor bleeding 1 (<1%) 14 (3%) ·· 21 (4%) 24 (5%) ··
Combined thrombosis and major bleeding events
Total catheter-related thromboses and major bleeding events 25 (6%) 31 (8%) 1·23 (0·83–1·52, 0·51) 41 (9%) 29 (6%) 0·84 (0·74–2·04, 0·17)
All thrombotic and major bleeding events 39 (10%) 37 (9%) 0·94 (0·61–1·44, 0·87) 44 (9%) 42 (9%) 0·95 (0·64–1·42, 0·89)
Data are number or number (%), unless otherwise indicated. INR=international normalised ratio.
Table 2: Thrombotic events
See Online for webﬁ gure
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stated (n=2). The sites of 36 non-catheter-related 
thrombotic events were lower limb (n=18), lung 
(pulmonary emboli; n=9), upper limb (n=4), inferior vena 
cava (n=2), subclavian vein (n=1), pulmonary vein (n=1), 
and portal vein (n=1). These events, with the exception of 
one upper-limb arterial thrombosis, were all venous.
Median time to a catheter-related thrombosis was 
32 days (IQR 13–76) from randomisation, and did not 
diﬀ er in the warfarin versus no warfarin (25 days vs 
32 days, p=0·71) or dose-adjusted warfarin versus 
ﬁ xed-dose warfarin (60 days vs 31 days, p=0·51) 
comparisons. Median time to all 121 catheter-related and 
non-catheter-related thromboses was 44 days (13–84). 
CVCs were patent for a median of 13·9 weeks (7·3–22·3) 
for all patients. The median duration of catheter patency 
was not signiﬁ cantly diﬀ erent across treatments (data not 
shown). 124 patients (8%) were classiﬁ ed as having one or 
more catheter-related infections; there were no signiﬁ cant 
diﬀ erences between treatments.
Although evidence suggested an excess of major 
bleeding events in patients on warfarin versus no warfarin 
and in patients on dose-adjusted warfarin versus ﬁ xed-dose 
warfarin, neither comparison was signiﬁ cant (table 2). 
When we restricted the results from the analysis to only 
those patients known to comply with their randomised 
treatment they were similar (7 [2%] of 376 vs 1 [<1%] of 390, 
RR 7·26, 95% CI 0·90–58·73, p=0·04 for warfarin vs no 
warfarin; and 14 [3%] of 423 vs 6 [1%] of 451, 2·49, 0·96–
6·41, p=0·07 for dose-adjusted warfarin vs ﬁ xed-dose 
warfarin). An increase in moderately and severely raised 
INR without major bleeding and an increase in minor 
bleeding were also noted (table 2). Warfarin, according to 
clinicians, might have contributed to the deaths of two 
patients receiving dose-adjusted warfarin; thrombosis was 
not known to contribute to death. 
In view of the ﬁ ne balance between the clinical 
consequences of thrombosis and major bleeding, we 
assessed a combined endpoint of thrombotic events and 
major bleeds. We found no signiﬁ cant diﬀ erence between 
treatment arms for either comparison (table 2). 
We analysed detailed INR readings from one centre 
with 54 patients on ﬁ xed-dose warfarin and 56 on 
dose-adjusted warfarin. INR measurements were taken 
on average six times for ﬁ xed-dose warfarin and 19 times 
for dose-adjusted warfarin groups for a median of 
1·8 (IQR 0·46–3·32) months and 5·1 months (2·61–6·69), 
respectively. Median INR for the ﬁ xed-dose warfarin 
group was 1·10 (1·04–1·24), and for dose-adjusted 
warfarin was 1·69 (1·43–1·93).
532 patients were still alive after a median follow-up of 
45 months (range 26–88). 921 (87%) of 1058 reported 
deaths were due to cancer, 53 (5%) to other causes, and 
84 (8%) to unknown causes. We did not note an overall 
survival advantage in patients taking warfarin compared 
with those in the no-warfarin group (hazard ratio 0·98, 
95% CI 0·77–1·25, p=0·26) or when we compared the 
t w o 
dosing schedules (0·91, 0·73–1·14, p=0·53; ﬁ gure 3).
Discussion
Our ﬁ ndings show that warfarin does not have a useful 
role in the prophylaxis of catheter-related thrombosis. 
The overall rate of symptomatic catheter-related 
thrombosis was low, which was in keeping with a general 
temporal trend during the study12 brought about by 
improved catheter design and care.13,14 However, the low 
event rate restricts the statistical power of all comparisons. 
Noteworthy, more clinicians than expected from the 
pretrial survey were certain of the indication for warfarin, 
perhaps because of the results of early studies. Compared 
with no warfarin, use of warfarin did not oﬀ er any 
advantage in reduction of the rate of catheter-related 
thrombosis. Similarly, warfarin did not reduce the rate 
of all thrombotic events or have any eﬀ ect on survival. 
When we compared ﬁ xed-dose and dose-adjusted 
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Figure 2: Time to catheter-related thrombosis
(A) Warfarin versus no warfarin. (B) Fixed-dose warfarin versus dose-adjusted warfarin.
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advantage with use of either dose; however, the numbers 
in each group were small (table 3). Conversely, 
dose-adjusted warfarin did signiﬁ cantly reduce the 
number of symptomatic catheter-related thromboses 
compared with ﬁ xed-dose warfarin but at an increased 
risk in terms of major bleeds and additional INR 
monitoring. This reduction in catheter-related 
thromboses with dose-adjusted versus ﬁ xed-dose 
warfarin does not translate into a reduction in all 
thrombotic events and, the dose eﬀ ect of warfarin is 
reduced when the combined endpoint of thrombosis 
plus major bleeding is assessed (table 2). However, for 
clinicians still wishing to oﬀ er prophylactic oral 
anticoagulation to patients with CVCs—eg, to patients at 
high thrombotic risk,15–17 and who are prepared to accept 
the related toxicity proﬁ le—dose-adjusted warfarin could 
be the most logical choice. The fewer than expected 
events across all comparisons was a limitation of the 
study, as was the absence of data gathering on patient 
history of venous thromboembolism and previous 
catheter insertions. These have been identiﬁ ed as 
signiﬁ cant risk factors for catheter-related thrombosis.15,16 
Exploratory subgroup analysis will be the topic of a 
future paper.
Our ﬁ ndings are in agreement with the results from 
more recent studies on thromboprophylaxis in patients 
with cancer receiving treatment through CVC. Bern 
and co-workers4 compared warfarin 1 mg per day for 
90 days with no warfarin in patients with cancer and 
long-term central venous catheters. Venous 
thromboemboli were detected by venography, done 
routinely and when patients were symptomatic, in 
15 (38%) of 40 patients in the no warfarin group 
compared with 4 (10%) of 42 on warfarin (p<0·001). 
Monreal and colleagues3 randomly assigned a similar 
group of patients to the low-molecular-weight heparin 
dalteparin (2500 IU per day, subcutaneously, for 90 days) 
or no dalteparin. Early trial closure was precipitated by 
diﬀ erential upper-limb thrombosis rates (1 [6%] of 16 in 
the dalteparin group vs 8 [62%] of 13 in the no dalteparin 
group, p=0·002), which were conﬁ rmed by routine 
venography. A Korean group18 randomly assigned 
80 patients with cancer receiving chemotherapy through 
CVCs to warfarin 1 mg versus no warfarin and reported 
thrombosis rates of 13% and 29%, respectively (p=0·07). 
Although small, the ﬁ ndings of these three trials3,4,18 
suggested a beneﬁ t of prophylactic anticoagulation by 
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Figure 3: Overall survival
(A) Warfarin versus no warfarin. Median survival 17 months (95% CI 14–20) in no-warfarin group and 19 months 
(16–22) in warfarin group. (B) Fixed-dose warfarin versus dose-adjusted warfarin. Median survival 21 months 
(17–24) in ﬁ xed-dose warfarin group and 21 months (19–25) in dose-adjusted warfarin group.












(95% CI, p value)
Catheter-related thrombotic events 24 (6%) 22 (7%) 1·10 (0·64–1·89, 0·72) 5 (3%) 2 (2%) 0·77 (0·15–3·87, 0·99)
All thrombotic events (catheter-related and non-catheter-related) 38 (9%) 28 (9%) 0·91 (0·57–1·45, 0·69) 13 (8%) 2 (2%) 0·29 (0·07–1·28, 0·10)
Major bleeding 1 (<1%) 3 (<1%) 3·74 (0·39–35·79, 0·33) 0 4 (5%) ·· (0·01)
Total major bleeding and catheter-related thrombotic events 25 (6%) 25 (8%) 1·25 (0·73–2·13, 0·51) 5 (3%) 6 (7%) 2·30 (0·72–7·32, 0·19)
Total major bleeding and all thrombotic events 39 (10%) 31 (10%) 0·99 (0·63–1·55, 0·99) 13 (8%) 6 (7%) 0·88 (0·35–2·24, 0·99)
Data are number (%), unless otherwise indicated. 
Table 3: Thrombotic events in secondary randomised comparisons
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toxicity. However, in other trials warfarin intervention 
did not result in any beneﬁ ts. Heaton and colleagues5 
assessed the eﬀ ects of ﬁ xed-dose warfarin at 1 mg per 
day versus no warfarin on thromboprophylaxis in 
88 patients with haematological neoplasms receiving 
chemotherapy through CVCs and noted no diﬀ erence in 
symptomatic thromboses (18% vs 12%, respectively, 
p=0·4). Similarly, Couban and colleagues6 recorded the 
number of symptomatic thrombotic events in a trial of 
255 patients (80% with haematological neoplasms) 
receiving warfarin 1 mg per day or placebo for 9 weeks. 
Overall catheter-related thrombotic rates were low; 
4·6% with warfarin and 4·0% with placebo (hazard 
ratio 1·2, 95% CI 0·37–3·94). To keep patients with 
cancer on warfarin within the target INR range is 
diﬃ  cult.19,20 Our analysis of INR showed a similar 
variability to other studies.19,20 We had diﬃ  culty in 
monitoring INR in patients receiving dose-adjusted 
warfarin in a few centres because clinicians used 
diﬀ erent monitoring protocols. Also, if the patient lived 
far from a cancer centre, primary-care practitioners were 
often asked to monitor INRs without robust systems 
being set up.
In trials, low-molecular-weight heparins have proven 
to be no more eﬀ ective than no treatment in the 
prophylaxis of catheter-related thrombosis. Verso and 
colleagues7 adopted a primary endpoint of thrombosis 
(measured at routine investigation) in a trial of 
enoxaparin (40 mg once per day for 6 weeks) versus 
placebo. In 385 patients with cancer, thrombosis rates 
were similar in the enoxaparin and placebo groups (14% 
vs 18%, p=0·35). Karthaus and colleagues8 showed no 
symptomatic thromboprophylactic eﬀ ect of dalteparin 
(5000 IU per day) compared with placebo (3·7% 
and 3·4%, respectively, p=0·88). Our results concur with 
the pooled estimate of Bern4 and Heaton5 and their 
colleagues trials, conﬁ rming no beneﬁ t from warfarin.21 
When data from this study were added to a previous 
meta-analysis of warfarin intervention versus no warfarin 
in the prophylaxis of thrombosis in patients with cancer 
receiving chemotherapy through CVCs,12 the earlier 
advantage noted with warfarin (odds ratio 0·58, 95% CI 
0·34–1·01, p=0·05) was reduced (0·75, 0·5–1·1, p=0·1; 
ﬁ gure 4).
When we considered the ﬁ ndings of these previous 
trials with our ﬁ ndings, we noted that the rate of 
symptomatic catheter-related thromboses reported in 
clinical trials has fallen substantially over the past decade.12 
The improvements in catheter technology, placement, 
and aftercare are contributing to this reduction.13,14 When 
any beneﬁ t of thromboprophylaxis was balanced against 
the risk of major bleeding, the combined outcome  showed 
no advantage with the use of any dose of warfarin. These 
ﬁ ndings only add to the assertion that the time has come 
to move on from warfarin for thromboprophylaxis in 
patients with cancer.
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